ADC Therapeutics (ADCT) Depreciation and Depletion (2023 - 2025)

ADC Therapeutics has disclosed Depreciation and Depletion across 3 years of filings, most recently posting $362000.0 for Q2 2025.

• Depreciation and Depletion for Q2 2025 came in at $362000.0, up 11.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $704000.0 (down 47.23% YoY), and the FY2025 annual result was $705000.0, down 47.15% from the prior year.
• Depreciation and Depletion came in at $362000.0 for Q2 2025 at ADC Therapeutics, up from $342000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $362000.0 in Q2 2025 to a low of $263000.0 in Q1 2023.
• The 3-year median for Depreciation and Depletion is $333000.0 (2023), against an average of $322500.0.
• Peak annual rise in Depreciation and Depletion reached 25.86% in 2024, while the deepest fall reached 1.79% in 2024.
• ADC Therapeutics' Depreciation and Depletion stood at $335000.0 in 2023, then climbed by 1.79% to $341000.0 in 2024, then advanced by 6.16% to $362000.0 in 2025.
• The last three Depreciation and Depletion figures came in at $362000.0 (Q2 2025), $342000.0 (Q1 2025), and $341000.0 (Q4 2024), per Business Quant data.